Fetal Sequencing From Maternal Blood Could Expand the Scope of Prenatal Rare Disease Testing

A technology that analyzes fetal DNA fragments in pregnant women’s blood could move prenatal genetic testing beyond a small number of common chromosomal abnormalities and toward thousands of rare genetic diseases. The Guardian reported that a research team involving the Broad Institute said this “noninvasive fetal sequencing” (NIFS) performed close to current invasive tests for most clinically meaningful genetic variants in validation data.

Current noninvasive prenatal testing is mostly used for specific chromosomal abnormalities such as Down syndrome. If ultrasound or other tests detect fetal abnormalities, clinicians often need to consider amniocentesis or chorionic villus sampling to obtain fetal- or placenta-related samples for further sequencing. These methods have strong diagnostic capability, but because they are invasive, pregnant women may hesitate because of miscarriage risk, anxiety, difficulty accessing the procedures, or cost.

The research team tested NIFS in 565 pregnancies, with the average gestational age at testing about 17 weeks. The report said the technology sequences short DNA fragments in maternal blood, then uses computational methods to reconstruct and interpret fetal genetic variants; compared with results from amniocentesis or chorionic villus sampling, it detected most clinically relevant variants. If subsequent studies confirm its reliability, NIFS could reduce the need for some invasive testing in genetic evaluations after fetal structural abnormalities are found.

The scientific significance of this advance is that it does not merely look for a small number of target variants, but attempts to analyze fetal genetic information at close to a whole-genome scale. The report noted that researchers believe its coverage could extend to diseases on multiple newborn sequencing and fetal anomaly gene panels, including rare diseases that, if known early, could affect pregnancy, delivery, or newborn care arrangements.

However, technical feasibility does not mean it should immediately be used as universal screening. The broader the screening, the more likely it is to encounter “variants of uncertain significance”: genetic sequences that appear different but cannot be clearly judged as to whether they will cause disease, when disease may occur, or how severe it may be. Such results could place heavy decision-making pressure on prospective parents, and could also put children after birth into unnecessary or excessive medical follow-up.

Currently available public reporting is still insufficient to determine how NIFS performs in different populations, at different gestational ages, with different fetal DNA fractions, or among generally low-risk pregnant women. If it is to be incorporated into routine prenatal care in the future, it will need not only larger-scale validation, but also clear rules on testing indications, the scope of result reporting, genetic counseling resources, and data privacy protections. The technology is most likely to have an impact first in situations where there are already ultrasound or other abnormal findings, rather than indiscriminately interpreting every fetal genome.